Treatment of patients with amiodarone-induced thyrotoxicosis type 2.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22747

Enrollment

Registered

2005-05-30

Start date

2004-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Treatment with methimazole and prednisone, methimazole and sodiumperchlorate or methimazole, sodiumperchlorate and prednisone.

Eligibility

Inclusion criteria

Inclusion criteria: TSH 25 pmol/l, normal or raised T3 , thyroid peroxidase antibodies <50 kU/l, TBII < 2.0 kU/l, amiodarone use, poor or no visualisation of thyroid gland on 99mTc-pertechnetate scintigraphy, no nodular goiter on ultrasound.

Exclusion criteria

Exclusion criteria: Very critical illness, drug or alcohol abuse, pregnancy, no informed consent.

Design outcomes

Primary

Measure	Time frame
Achievement of euthyroidism (TSH >0.4 mE/L at 3 and 6 months.	—

Secondary

Measure	Time frame
Development side-effects.	—

Contacts

Public ContactW.M. Wiersinga

Academic Medical Center (AMC), Department of Endocrinology and Metabolism, P.O. Box 22660

w.m.wiersinga@amc.uva.nl+31 (0)20 5669111

Outcome results